UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

Nature communications, 2024-05, Vol.15 (1), p.3962-3962, Article 3962

2024

Volltextzugriff (PDF)

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

PloS one, 2018-09, Vol.13 (9), p.e0204308-e0204308

2018

Volltextzugriff (PDF)

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Annals of hepatology, 2024-01, Vol.29 (1), p.101133-101133, Article 101133

2024

Volltextzugriff (PDF)

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.124-134.e1

2024

Volltextzugriff (PDF)

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

The lancet. Gastroenterology & hepatology, 2023-06, Vol.8 (6), p.511-522

2023

Volltextzugriff (PDF)

Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging

IEEE transactions on ultrasonics, ferroelectrics, and frequency control, 2015-01, Vol.62 (1), p.165-175

2015

Volltextzugriff (PDF)

830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Sex Differences in NAFLD: State of the Art and Identification of Research Gaps

Hepatology (Baltimore, Md.), 2019-09, Vol.70 (4), p.1457-1469

2019

Volltextzugriff (PDF)

136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1148-P: Cenicriviroc Safety in over 1,200 Subjects

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1839-P: Glycemic Control Impacts Severity of Hepatic Fibrosis in NAFLD/NASH

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply

Alimentary pharmacology & therapeutics, 2022-07, Vol.56 (1), p.182-183

2022

Volltextzugriff (PDF)

Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH

Clinical liver disease (Malden, Mass.), 2021-01, Vol.17 (1), p.29-32

2021

Volltextzugriff (PDF)

Differential Dna Methylation in Whole Blood Reflects that in Liver and Distinguishes Patients with Advanced Nafld Fibrosis from Those with Normal Histology: A Potential Non-Invasive Tool

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1069-S1070

2017

Volltextzugriff (PDF)

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

The American journal of gastroenterology, 2001, Vol.96 (9), p.2711-2717

2001

Volltextzugriff (PDF)

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Issue Cover

Liver international, 2020-04, Vol.40 (4), p.i-i

2020

Volltextzugriff (PDF)

Reply: Is oil red‐O staining and digital image analysis the gold standard for quantifying steatosis in the liver?

Hepatology (Baltimore, Md.), 2010-05, Vol.51 (5), p.1859-1860

Abdelmalek, Manal F.

2010

Volltextzugriff (PDF)

Reply to Kim et al

The American journal of gastroenterology, 2017-05, Vol.112 (5), p.807-808

2017

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease

North Carolina medical journal (Durham, N.C.), 2016-05, Vol.77 (3), p.216-219

2016

Volltextzugriff (PDF)

Mo1557 Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements With Obeticholic Acid

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1144-S1144

2016

Volltextzugriff (PDF)

Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1055-S1055

2017

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(104)

Publikationsform

Sprache

Englisch
(112)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Fibrosis
(14)
Gastroenterology And Hepatology
(12)
Humans
(11)
Fatty Liver
(9)
Female
(7)
Liver
(7)
Liver Diseases
(7)
Male
(7)
Diabetes
(6)
Diabetes Mellitus
(6)
Biopsy
(5)
Cirrhosis
(5)
Metabolism
(5)
Middle Aged
(5)
Non-Alcoholic Fatty Liver Disease - Diagnosis
(5)
Adult
(4)
Alcohol
(4)
Inflammation
(4)
Insulin Resistance
(4)
Liver Cirrhosis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging

830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control

844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels

Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms

1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study

Sex Differences in NAFLD: State of the Art and Identification of Research Gaps

136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis

1148-P: Cenicriviroc Safety in over 1,200 Subjects

1839-P: Glycemic Control Impacts Severity of Hepatic Fibrosis in NAFLD/NASH

Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply

Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH

Differential Dna Methylation in Whole Blood Reflects that in Liver and Distinguishes Patients with Advanced Nafld Fibrosis from Those with Normal Histology: A Potential Non-Invasive Tool

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Issue Cover

Reply: Is oil red‐O staining and digital image analysis the gold standard for quantifying steatosis in the liver?

Reply to Kim et al

Nonalcoholic Fatty Liver Disease

Mo1557 Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements With Obeticholic Acid

Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Aktive Filter

Suchergebnisse filtern